DENDROPHILIN, NOVO-PYREXAL, MULTIVAX AND IAXO COMPOUNDS ARE NOT APPROVED FOR HUMAN, DIAGNOSTICS OR VETERINARY USE. USE OF THIS PRODUCT FOR HUMAN OR ANIMAL TESTING IS EXTREMELY HAZARDOUS AND MAY RESULT IN DISEASE, SEVERE INJURY, OR DEATH.
The Innaxon website has been created solely for information purposes. It is not intended to be used for advice or recommendation in any field including medicinal and financial, and should not be relied upon for such purposes.
The content of the site is provided on an “as is” basis and Innaxon makes no representations or warranties in respect of it.
Use of the website will be regarded by Innaxon as an acceptance by the user of the risk of receiving incomplete, inaccurate or inappropriate information. The user accesses this website and uses its contents and links to other websites at his risk.
Innaxon accepts no liability for damages or injury of any kind whatsoever that may arise directly or indirectly there from, including damages resulting from computer viruses.The content of this website is protected by copyright laws and is the property of Innaxon.
Users are prohibited from using it for commercial purposes without first obtaining the written consent of Innaxon. Use of the Innaxon website shall be governed by and interpreted in accordance with the laws of England and any communications from users in respect of it shall be on a non-confidential basis and may be used by Innaxon for any purposes whatsoever.
Research Use Only, 3rd Party Patents and Patent Applications
Products currently covered by valid patents are offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Section 68B of the Patents Act of 1953 in New Zealand; (vi) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (vii) such similar laws and rules as may apply in various other countries. In the European Union, equivalent exemptions are allowed under the terms of EC Directives 2001/82/EC (as amended by Directive 2004/28/EC) and 2001/83/EC (as amended by Directives 2002/98/EC, 2003/63/EC, 2004/24/EC and 2004/27/EC). Any patent infringement issue and resulting liability is solely at buyer’s risk.
All content contained in this website is the property of innaxon and may be used only with the expressed written permission of innaxon. Copyright © 2010-2020 Innaxon. All rights reserved.
Innaxon®, LPS Biosciences®, Dendrophilin®, IMMUNOKINE®, MultiVAX® and Novo-Pyrexal® are registered trademarks of Innaxon.